Chimerix, Inc. (CMRX)

NASDAQ: CMRX · Real-Time Price · USD
0.990
0.00 (0.00%)
Nov 4, 2024, 4:00 PM EST - Market closed
0.00%
Market Cap 88.74M
Revenue (ttm) 144,000
Net Income (ttm) -84.70M
Shares Out 89.64M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 259,391
Open 0.977
Previous Close 0.990
Day's Range 0.967 - 1.050
52-Week Range 0.750 - 1.300
Beta 1.13
Analysts Strong Buy
Price Target 11.00 (+1,011.11%)
Earnings Date Nov 7, 2024

About CMRX

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary c... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 11, 2013
Employees 72
Stock Exchange NASDAQ
Ticker Symbol CMRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for CMRX stock is "Strong Buy" and the 12-month stock price forecast is $11.0.

Price Target
$11.0
(1,011.11% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024

DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...

3 days ago - GlobeNewsWire

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement awar...

17 days ago - GlobeNewsWire

Chimerix, Inc. (CMRX) Q2 2024 Earnings Call Transcript

Chimerix, Inc. (NASDAQ:CMRX) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Mike Andriole - President and Chief Executive Of...

2 months ago - Seeking Alpha

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to t...

4 months ago - GlobeNewsWire

Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference

DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients ...

5 months ago - GlobeNewsWire

Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript

Chimerix, Inc. (NASDAQ:CMRX) Q1 2024 Earnings Conference Call May 1, 2024 8:30 AM ET Company Participants Will O'Connor – Stern Investor Relations Mike Andriole – President and Chief Executive Office...

6 months ago - Seeking Alpha

Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 –

6 months ago - GlobeNewsWire

Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024

DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fa...

6 months ago - GlobeNewsWire

Chimerix: Tackling A Strong Unmet Need With Promising Data

Chimerix, Inc. is a biotech company focused on developing novel treatments for high-grade glioma and other therapies. Their main clinical asset, doraviprone, has shown promising results in treating H3...

8 months ago - Seeking Alpha

Chimerix, Inc. (CMRX) Q4 2023 Earnings Call Transcript

Chimerix, Inc. (CMRX) Q4 2023 Earnings Call Transcript

8 months ago - Seeking Alpha

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 –

8 months ago - GlobeNewsWire

Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024

DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...

9 months ago - GlobeNewsWire

Chimerix Appoints Lisa Decker to Board of Directors

Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Exp...

11 months ago - GlobeNewsWire

Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer

DURHAM, N.C., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...

1 year ago - GlobeNewsWire

Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development Seasoned Executive Brings More Than 25 Years of Industry...

1 year ago - GlobeNewsWire

Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update

– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 –

1 year ago - GlobeNewsWire

Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023

DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...

1 year ago - GlobeNewsWire

Chimerix: Dangerous Road, Thesis Intact

Chimerix meets financial expectations during Q2, 2023 earnings call. Investment thesis for Chimerix focuses on its ONC201 study expected to read out in 2026. Company has high risk of loss despite expe...

1 year ago - Seeking Alpha

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"

Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control

1 year ago - GlobeNewsWire

Chimerix, Inc. (CMRX) Q2 2023 Earnings Call Transcript

Chimerix, Inc. (NASDAQ:CMRX) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Michelle Laspaluto - Vice President of Strategic Planning and Investor Relations Mike Andr...

1 year ago - Seeking Alpha

Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update

– Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries; Reiterate First Interim Overall Survival Analysis Expected Early 2025 –

1 year ago - GlobeNewsWire

Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023

DURHAM, N.C., July 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...

1 year ago - GlobeNewsWire

Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer

Mike Sherman to Transition to Chair of the Board of Directors Martha Demski to Assume Role of Lead Independent Director DURHAM, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a ...

1 year ago - GlobeNewsWire

Chimerix: A High-Risk 'Lottery Ticket'

Today, we put the spotlight on Chimerix, Inc. for the first time in 12 months. The company is advancing its primary oncology candidate in development, has a potentially large market, and sells for les...

1 year ago - Seeking Alpha

Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White House

DURHAM, N.C., May 25, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients faci...

1 year ago - GlobeNewsWire